



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: Ibutilide Fumarate

产品别名: 富马酸伊布利特; U70226E

生物活性:

| Description | Ibutilide fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. Target: Calcium Channel Ibutilide fumarate is the first 'pure' class III antiarrhythmic drug to become available. Its predominant action is prolongation of the myocardial action potential duration. Intravenous ibutilide 0.01 to 0.025 mg/kg or 1 to 2 mg successfully converted atrial flutter or fibrillation to sinus rhythm in 33 to 49% of patients in 2 placebo-controlled trials involving 439 patients with sustained arrhythmia [1]. Ibutilide fumarate appears to be an effective alternative method for rapid conversion of recent-onset AF or AFI. The drug may be particularly useful in patients who have undergone recent cardiac surgery or those who are not ideal candidates for DCC [2]. | | | | | | | | | | | | | | | | | |
|--|---|---------------------------|------------------------------|------------|-------|-------|------|-----------|------------|------------|------|-----------|-----------|-----------|-------|-----------|-----------|-----------|
| In Vitro: DMSO : ≥ 50 mg/mL (112.97 mM) H ₂ O : 50 mg/mL (112.97 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. | <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent / Mass Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td>2.2593 mL</td><td>11.2966 mL</td><td>22.5933 mL</td></tr><tr><td>5 mM</td><td>0.4519 mL</td><td>2.2593 mL</td><td>4.5187 mL</td></tr><tr><td>10 mM</td><td>0.2259 mL</td><td>1.1297 mL</td><td>2.2593 mL</td></tr></tbody></table> | Preparing Stock Solutions | Solvent / Mass Concentration | 1 mg | 5 mg | 10 mg | 1 mM | 2.2593 mL | 11.2966 mL | 22.5933 mL | 5 mM | 0.4519 mL | 2.2593 mL | 4.5187 mL | 10 mM | 0.2259 mL | 1.1297 mL | 2.2593 mL |
| Preparing Stock Solutions | Solvent / Mass Concentration | | 1 mg | 5 mg | 10 mg | | | | | | | | | | | | | |
| | 1 mM | 2.2593 mL | 11.2966 mL | 22.5933 mL | | | | | | | | | | | | | | |
| 5 mM | 0.4519 mL | 2.2593 mL | 4.5187 mL | | | | | | | | | | | | | | | |
| 10 mM | 0.2259 mL | 1.1297 mL | 2.2593 mL | | | | | | | | | | | | | | | |
| Solvent&Solubility 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (5.65 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀, 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。 2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (5.65 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理 | | | | | | | | | | | | | | | | | | |



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

| | |
|-------------------|--|
| | <p>盐水水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (5.65 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p> |
| References | <p>[1]. Foster, R.H., M.I. Wilde, and A. Markham, Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs, 1997. 54(2): p. 312-30.</p> <p>[2]. Howard, P.A., Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother, 1999. 33(1): p. 38-47.</p> |



源叶生物